1	Older age, lack of vaccination and infection with variants other than Omicron associated
2	with severity of COVID-19 and in-hospital mortality in Pakistan
3	
5	
4	Muhammad Zain Mushtaq ¹ *, Nosheen Nasir ¹ *, Syed Faisal Mahmood ¹ , Sara Khan ¹ , Akbar
5	Kanji ² , Asghar Nasir ² , Uzma Bashir Aamir ³ and Zahra Hasan ² #
6	*Contributed equally
7	¹ Department of Medicine, The Aga Khan University, Karachi, Pakistan
8	² Department of Pathology and Laboratory Medicine, The Aga Khan University, Karachi,
9	Pakistan
10	³ World Health Organization, Pakistan
11	
12	#Corresponding author
13	Zahra Hasan, PhD, Professor, Department of Pathology and Laboratory Medicine, The Aga
14	Khan University, Stadium Road, P.O.Box 3500, Karachi 74800, Pakistan. Email:
15	zahra.hasan@aku.edu
16	
17	Key words
18	Omicron, COVID-19, vaccinations, severity, Pakistan
19	
20	
21	
22	
23	
24	

25 Abstract

- Objectives: We investigated factors associated with COVID-19 disease severity and in-hospital
 mortality in a low-middle income setting.
- 28 Methods: Records of 197 adult COVID-19 patients admitted to the Aga Khan University

Hospital, Karachi between April 2021 and February 2022 were reviewed. Clinical data

- 30 including, that of SARS-CoV-2 variants was collected.
- **Results:** The median age of the patients was 55 years and 51.8% were males. 48.2 % of patients
- had non-severe disease, while 52.8% had severe/critical disease. Hypertension (48%) and
- diabetes mellitus (41.3%) were most common comorbid conditions. Omicron (55.3%), Beta
- 34 (14.7%), Alpha (13.7%), Delta (12.7%) and Gamma (3.6%) were identified in patients. The risk
- of severe disease was higher in those aged above 50 years (OR 5.73; 95%CI [2.45-13.7]) and in
- 36 diabetics (OR 4.24; 95% CI[1.82-9.85]). Full vaccination (OR 0.25; 95% CI [0.11-0.58]) or
- infection with Omicron variants (OR 0.42; 95% CI[0.23-0.74]) reduced disease severity. Age >
- 38 50 (OR 5.07; 95% CI [1.92-13.42]) and presence of myocardial infarction (OR 5.11; 95%
- 39 CI[1.45-17.93]) was associated with increased mortality, but infection with Omicron (OR 0.22
- 40 95% CI 0.10-0.53]) reduced risk.
- 41 **Conclusions**:
- 42 Vaccination was found to protect against severe COVID-19 regardless of the infecting variant
- 43 and is recommended especially, in those aged over 50 years and with co-morbid conditions.
- 44

46 Introduction

47 COVID-19 (Coronavirus Disease 2019) has been diagnosed in greater than 654 million cases with 48 a global death toll of 6.67 million [1]. Global epidemiology of COVID-19 has varied greatly, with 49 the highest burden of deaths to date observed in the USA, Brazil and India [1]. Low middle-income 50 countries such as Pakistan and those in Sub-Saharan and East Africa have been relatively spared 51 and mortality due to COVID-19 has been comparatively lower or under reported [2].

Pakistan has thus far experienced 5 distinct pandemic waves, the first, between March and July 52 53 2020, the second betweenOctober 2020 and January 2021, the third, between March and May 2021, the fourth between July and September 2021 and the fifth between December and February 54 55 2022 [3]. As of December 30 2022, COVID-19 has been diagnosed in 1.58 million cases in Pakistan with the number of deaths nearing 31,000 [1]. Of the COVID-19 cases in Pakistan, 56 57 591,553 (36%) COVID-19 cases were from Sindh province with 40% reported from the city of Karachi [4]. The case fatality rate (CFR) has been 2% with some regional variations. It is of interest 58 59 to understand the factors associated with COVID-19 severity in the local context. In an earlier study conducted at our center during the first wave of COVID-19; 30% of patients had severe to 60 61 critical disease at presentation with age and critical disease (identified by septic shock and multiorgan dysfunction) were independently associated with mortality [5]. 62

COVID-19 vaccination was first introduced at the start of 2021 [6] and rolled out in stages based
on both access and availability in different populations. As in other parts of the world, this
contributed to slowing down the pandemic, controlling both morbidity and mortality from COVID19 [7].

Variants carrying mutations in the spike glycoprotein have been described by the World Health Organization to be variants of concern (VoCs) and include, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529) [8]. VoCs exhibit genetic modifications linked to increased transmissibility, more severe disease, reduced efficacy of vaccinations or medical treatment [9]. A study from Canada reported that Alpha, Beta, and Gamma were the main variants causing COVID-19 in 2020 with Alpha being the most prevalent variant [10]. Studies from Brazil and Singapore had reported increased severity of disease in COVID-19 patients with
the Gamma variant and Delta variant respectively [11].

75 G, L and S clade SARS-CoV-2 strains were shown to be present in the first wave of COVID-19 in Pakistan from March until August 2020 [12]. There was a shift in predominance from Alpha 76 77 to Delta variants between April and July 2021 and then again from Delta to Omicron variants between December and February 2022 [13]. The Omicron variant which emerged in the latter 78 79 half of 2021, had more than 50 mutations across the genome, resulting in reduced vaccine efficacy with a greater chance of breakthrough infections [14]. Omicron was found to be more 80 81 transmissible compared with other variants, with a greater chance of re-infections however, with 82 a reduction in hospital associated mortality [15].

Throughout the pandemic, COVID-19 related mortality in Pakistan remained low when compared to the other countries [16]. However, the clinical outcomes of patients with severe COVID-19 related to the infecting variants remain to be elucidated. We, therefore, assessed the risk factors, clinical presentation and outcomes in relation to the VoC in patients with COVID-19 in Karachi, Pakistan.

88 Methods

This was a retrospective cohort study of adults with a PCR confirmed COVID-19 patients admitted
to the Aga Khan University Hospital (a 700-bedded tertiary care hospital in Karachi, Pakistan),
between April 2021 and February 2022.

All COVID-19 cases had a SARS-CoV-2 PCR positive respiratory sample using the SARS-CoV2 Cobas 6800 Roche assay, at the AKUH Clinical Laboratories, Karachi, Pakistan. The CT
(crossing threshold) value of each positive SARS-CoV-2 sample was noted. The cases chosen for
review were those for whom SARS-CoV-2 VoC testing had been conducted as part of a World
Health Organization supported ongoing genomic surveillance effort [17].

Data was collected on symptoms at presentation, treatment, duration of illness, outcomes and also, COVID-19 vaccination. Laboratory and radiological data were collected for all cases. COVID-19 severity was categorized into non-severe in patients who have oxygen saturation \ge 94% on room air, severe in those who have an oxygen saturation of < 94% and require supplemental oxygen support and critical in those who have respiratory failure, shock and/or multiorgan dysfunction [18]. WHO ordinal score for the severity of COVID-19 [19], length of hospital stay and in-hospital mortality were also recorded. Individuals who had received both doses of a two-dose vaccine regimen were categorized as 'Fully vaccinated', those who had received one dose of a two-dose vaccine regimen were categorized as 'Partially vaccinated' and those who had not yet received a single dose of COVID-19 vaccination were classified as 'Unvaccinated'.

107 Identification of VoC

Isolates were screened for VoC; Alpha, Beta, Gamma, Delta and Omicron lineage associatedmutations using a PCR-based approach [13].

110 Statistical Analysis

111 Median and interquartile range was reported for continuous variables such as age and length of 112 stay and frequency and percentages were used to describe categorical variables such as gender and 113 mortality. Comparison between categorical variables was determined using Chi-square test or 114 Fischer exact test where appropriate. P-value of < 0.05 was considered significant. Logistic 115 regression analysis was performed to examine the effect of each exposure variable on the severity 116 of illness and in-hospital mortality and adjusted Odds ratios (OR) and their 95% confidence 117 intervals (CI) were estimated. Data was analyzed using STATA version 12.0.

118

119 **Results**

120 Description of COVID-19 cases

We studied the clinical characteristics and disease outcomes of n=197 COVID-19 patients 121 122 admitted at AKUH between April 2021 and February 2022, to investigate the relationship between disease outcomes and SARS-CoV-2 infecting variants. Three COVID-19 waves were observed in 123 124 Pakistan during this study period (Supplementary Figure 1A). COVID-19 mortality was observed to be lower in the period between December 2021 and February 2022, as compared with the earlier 125 126 two waves (Supplementary Figure 1B). Notably, cases in April 2021 were mostly associated with 127 Alpha variants whilst those in July and August 2021 were associated with the Delta wave in Pakistan [20]. 128

The median age of the patients was 55 years (IQR 34-70 years) and 51.8% (n=102) were males, Supplementary Table 1. Hypertension (48%) and diabetes (41.3%) were the most common comorbid conditions. There were 23 pregnant patients (24.2% of females) and most of them were identified on screening before delivery. Amongst the pregnant women, 8 (34.7%) developed obstetric complications including intrauterine fetal demise in two cases.

Upon admission, 48.2 % of patients had non-severe disease, while 51.8% had severe/critical 134 disease. Fifty percent of patients had received systemic corticosteroids. Most patients survived 135 (70.6%) till the time of discharge while 38 (19.3%)patients died and 20 (10.2 %) left against 136 137 medical advice (Supplementary Table 1). Vaccination data was available for 154 patients. 46.7% of study subjects were unvaccinated and 30 % were vaccinated, of which all but three individuals 138 were fully vaccinated. Complications occurred in 27.4% patients (Supplementary Table 1). The 139 140 most frequent complication was acute kidney injury in 14.7%, followed by myocardial infarction in 9.1% and pneumothorax/pneumomediastinum in 3.6% patients. 141

The Omicron variant was found in 55.3% of patients, with Alpha variants in 13.7%, Beta in 14.7%
and Delta in 12.7% of cases. As these were in a relatively smaller number compared with Omicron,
we combined cases with Alpha, Beta, Delta and Gamma variants into a non-Omicron group for
further comparative analysis.

146 Vaccination data were available for 154 out of 197 patients. 46.7% of patients were unvaccinated147 and 30 % were fully-vaccinated, and 1.5% were partially-vaccinated.

148

149 Factors associated with severe COVID-19

We investigated the factors associated with severe COVID-19 by stratifying the study group into those with non-severe as compared with severe/critical disease. Age, clinical characteristics, vaccination status and infecting SARS-CoV-2 variants were all compared between the two subgroups. Most patients who developed severe disease were older than 50 years (p<0.001) and were 12 (p<0.001) or dischared (p<0.001) and increased length of hospital stay (p<0.001). Vaccination (OR 0.45; 95% CI[0.23-0.88]), p<0.001 was associated with non-severe disease. Infection with the Omicron variant was associated with non-severe disease (OR 0.42; 95% CI[0.23-0.74]),

157 p=0.003.

158 In a multivariate analysis, the independent risk factors for severe/critical disease were found to be

age greater than or equal 50 years of (aOR 5.73; 95% CI[2.45-13.7]) and presence of diabetes

160 mellitus (aOR 4.24; 95% CI[1.82-9.85]) whereas being fully vaccinated (aOR 0.25; 95% CI[0.11-

161 0.58]) were found to be protective against severe/critical disease (Table 2).

162

163 Factors associated with mortality

Factors associated with in-hospital mortality in our COVID-19 patient cohort were determined 164 165 (after excluding 20 patients who left against medical advice, Supplementary Table 1). The median 166 age of those who died was 64 years whilst those who survived was 48 years, Table 3. A univariate analysis showed age greater than or equal to 50 years (OR=5.73; (95% CI: 2.25-14.6), p=0.001; 167 the presence of co-infections or secondary infections (OR:2.45; 95%CI:1.08-5.58), p=0.032, 168 169 presence of complications such as myocardial infarction (MI) (OR:5.03; 95% CI: 1.69-14.9), 170 p=0.004, acute kidney injury (AKI) (OR:3.78; 95%CI: 1.48-9.61), p=0.005, having pneumothorax or pneumomediastinum (OR:8.05; 95%CI:1.42-45.8), p=0.019 and being unvaccinated (OR: 2.94; 171 95% CI:1.02-8.39), p=0.044, all to associated with greater risk of death. Infection with Omicron 172 as compared with non-Omicron variants was associated with survival (OR:0.28; 95% CI: 0.13-173 0.61), p=0.001. 174

A multivariate analysis run after adjusting for confounding and effect modification from other variables further confirmed in-hospital mortality were found to be associated with age greater than 50 years (aOR 5.07; 95% CI [1.92-13.42]), p=0.001, and the presence of MI (aOR 5.11; 95% CI[1.45-17.93]), p=0.001. Infection with the Omicron variant was associated with survival (aOR: 0.22; 95% CI: 0.10-0.53), p=0.001.

180

181 Viral loads were higher in Omicron infected individuals

Higher SARS-CoV-2 viral loads have been associated with more severe disease. We determined
the viral loads present in respiratory specimens and analysed them according to the VoC. The CT
of SARS-CoV-2 target gene amplification was used as a marker of viral loads. We found a
significant difference between the CT values of the VoC, Figure 1, p=0.015, Kruskal-Wallis

analysis. In particular, the CT values of Omicron variants were lower, reflecting significantly
higher viral loads as compared with the Alpha variant, p=0.0005.

188

189 Discussion

We conducted a hospital-based analysis of the association of SARS-CoV-2 VoC with clinical outcomes in patients with COVID-19 from Karachi, Pakistan between April 2021 to February 2022. Diabetes mellitus, hypertension, chronic kidney disease, age over 50 years, and critical disease on presentation were associated with higher mortality. In our cohort, a large proportion of patients were unvaccinated and nearly half developed critical disease. Furthermore, it was noted that infection caused by the omicron variant was associated with significantly lower risk of severe disease at presentation as well as reduced mortality rates.

Omicron variant wave peaked in January 2022 in Pakistan and it was related to highest number of cases since the beginning of the pandemic [1, 21]. In many European countries, the case fatality rate from infections with the Omicron variant was significantly lower as compared with Delta, despite the higher rate of new infections [22]. The period between April and December 2021, was dominated by the Alpha variant then followed by the emergence of the Beta variant in May and the Delta variant in July 2021 [23]. A population based study from UK reported an increase in deaths due to Alpha variants from 2.5 to 4.1 per 1000 detected cases [24].

During the first year of the pandemic (2020) in Karachi, we had observed that severe to critical disease at presentation, and age more than 60 years and critical disease to be independently associated with mortality[5]. This trend remained consistent in 2021 and 2022 except, that patients infected with Omicron variant had lesser odds of dying of COVID-19 as compared with non-Omicron variants, matching previous reports [25]. This fits with reports from South Africa that showed the Omicron wave had a reduced COVID-19 related mortality in patients aged 50 years and above [26].

The majority of our vaccinated study subjects were infected with the Omicron variant likely due to surge in January 2022, and the higher risk of breakthrough infections seen with this variant. Importantly, the Omicron variant had lower CT values associated with higher viral loads as compared with the Alpha variant. This differs from previous variants where genome-wise analysis of SARS-CoV-2 have demonstrated higher viral loads to be associated with increased disease
severity [27].

Recent reports show that Omicron variant caused less severe disease across multiple countries in
the context of different kinds of COVID-19 vaccinations [15]. In our study, vaccinated individuals
were found to have a reduced risk of mortality from COVID-19. This matches previous reports
which have shown effectiveness of COVID-19 vaccines in protection against severe disease [7,
28].

222 A limitation of our study that it is from a single-center tertiary care facility. Further, our sample size was relatively small and we did not have complete vaccination details for all study subjects. 223 224 Unfortunately, we were unable to collection information regarding vaccination from all cases. 225 During the study period, the most frequently administered vaccines in Pakistan were, BBIBP-CorV 226 (Sinopharm), SinoVac and CanSinoBio. It has been shown that BBIBP-CorV vaccination was protective against severe COVID-19 in Pakistan during the Delta wave [29]. An efficacy study of 227 228 different vaccines used in Pakistan has shown that inactivated virus type of vaccinations were moderately effective against symptomatic COVID-19, less effective than mRNA vaccination [30]. 229 We were unable to obtain information on the vaccination type from all subjects therefore, our study 230 cannot provide insights on the impact of any specific COVID-19 vaccine. However, this provides 231 232 key information as to the impact of VoC and its impact on severity of illness and mortality in hospitalized patients with COVID-19 in Pakistan. 233

In summary, we describe the pattern of SARS-CoV-2 VoCs present in the hospitalized population of COVID-19 cases over the second, third and fourth waves in Pakistan, from April 2021 until February 2022. We observed reduced disease severity and mortality due to the Omicron variant as compared with non-Omicron VoCs. Our findings are in accordance with the trends seen in national data for morbidity and mortality due to COVID-19. Finally, our data reveals that the introduction of VoCs was associated with successive COVID-19 waves. However, presence of Omicron was associated with reduced likelihood of death in our patient population.

241

242 Ethics Statement

This work complies with the policies for Ethical Consent as per Helsinki Declaration. The work received approval from the Ethical Review Committee of the Aga Khan University (study reference no. 2021-6232-19404).

246 Acknowledgements

Funding for SARS-CoV-2 variant testing was supported by the World Health Organization,
Pakistan and through a COVID-19 Research Rapid Grant from the Higher Education Commission,
Pakistan.

250 Authorship Contributions

251 The study was designed and supervised by ZH. MZM and NN contributed equally in data analysis

and preparation of the manuscript draft. SK, SFM, MZM and NN collected and analysed data. AK

and AN conducted the laboratory testing and data analysis. ZH and UBA secured funding for the

study. All authors have approved the manuscript submission.

255 **Contributions**

256 Thanks to Azra Samreen and Ali Raza Bukhari for their technical assistance. Thanks to M Asif

257 Syed and Mansoor Wassan, Department of Health, Sindh, for facilitation with COVID-19

258 vaccination data.

259

260 **References**

- JHU, COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at 261 1. 262 Johns Hopkins University. 28 February 2022. 263 2. Maeda, J.M. and J.N. Nkengasong, The puzzle of the COVID-19 pandemic in Africa. Science, 2021. 371(6524): p. 27-28. 264 265 3. Pakistan, G.o. COVID-19 Health Advisory Platform. Ministry of National Health Services Regulations and Coordination. 2021 31 July 2021]; Available from: https://covid.gov.pk/. 266 267 Department, H. Daily Situation Report. 2022 30 December 2022]. 4. Nasir, N., et al., Clinical characteristics and outcomes of COVID-19: Experience at a major tertiary 268 5. care center in Pakistan. J Infect Dev Ctries, 2021. 15(4): p. 480-489. 269 Pakistan receives first consignment of COVID-19 vaccines via COVAX Facility. 2021, EMRO, WHO: 270 6. http://www.emro.who.int/media/news/pakistan-receives-first-consignment-of-covid-19-271 272 vaccines-via-covax-facility.html. Chen, X., et al., Impact of vaccination on the COVID-19 pandemic in U.S. states. Sci Rep, 2022. 273 7.
- 274 **12**(1): p. 1554.

275	0	WILLO Tradius CARC Cold Quariante Quad Contomber 2021, Augilable from
275	8.	WHO. <i>Tracking SARS-CoV-2 variants</i> . 23rd September, 2021; Available from:
276	-	https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
277	9.	Zeyaullah, M., et al., COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health
278		<i>Concern.</i> Front Genet, 2021. 12 : p. 693916.
279	10.	Tuite, A., et al., COVID-19 hospitalizations, ICU admissions and deaths associated with the new
280		variants of concern. Sci Briefs Ont COVID-19 Sci Advis Table, 2021. 1: p. 18.
281	11.	Nonaka, C.K.V., et al., SARS-CoV-2 variant of concern P.1 (Gamma) infection in young and
282		middle-aged patients admitted to the intensive care units of a single hospital in Salvador,
283		northeast Brazil, February 2021. Int J Infect Dis, 2021.
284	12.	Ghanchi, N.K., et al., Higher entropy observed in SAR-CoV-2 genomes from the first COVID-19
285		wave in Pakistan PLoS ONE, 2021. 16(8)(e0256451): p.
286		https://doi.org/10.1371/journal.pone.0256451
287	13.	Nasir, A., et al. SARS-CoV-2 Variants of Concern (VOC) Alpha, Beta, Gamma, Delta, and
288	201	Omicroncoincident with consecutive pandemic waves in Pakistan. medRxiv, 2022.
289	14.	Iketani, S., et al., Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature, 2022.
205	15.	Beraud, G., et al., Impact of vaccination on the presence and severity of symptoms of
	15.	
291		hospitalised patients with an infection by the omicron variant (B.1.1.529) of the SARS-cov-2
292	4.6	(subvariant BA.1). Clinical Microbiology and Infection.
293	16.	Edouard Mathieu, H.R., Lucas Rodés-Guirao, Cameron Appel, Daniel Gavrilov, Charlie Giattino,
294		Joe Hasell, Bobbie Macdonald, Saloni Dattani, Diana Beltekian, Esteban Ortiz-Ospina, and Max
295		Roser, Coronavirus Pandemic (COVID-19). Our World in Data, 2020.
296	17.	Zahra, H., et al., Changing SARS-CoV-2 variants in Karachi, Pakistan from alpha to delta through
297		COVID-19 waves three and four. Research Square, 2021.
298	18.	NIH, U. Clinical Spectrum of SARS-CoV-2 Infection. COVID-19 Treatment Guidelines 2022
299		September 26, 2022].
300	19.	WHO, novel Coronavirus COVID-19 Therapeutic Trial Synopsis, in R&D Blueprint. 2020.
301	20.	Hasan, Z., et al., Changing SARS-CoV-2 variants in Karachi, Pakistan from alpha to delta through
302		COVID-19 waves three and four. Research Square. doi.10.21203/rs.3.rs-828919/v1 2021.
303	21.	Umair, M., et al., Tracking down B.1.351 SARS-CoV-2 variant in Pakistan through genomic
304		<i>surveillance.</i> J Med Virol, 2022. 94 (1): p. 32-34.
305	22.	Nyberg, T., et al., Comparative analysis of the risks of hospitalisation and death associated with
306		SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.
307		Lancet, 2022. 399 (10332): p. 1303-1312.
308	23.	Umair, M., Ikram, A., Salman, M., Haider, S.A., Badar, N., Rehman, Z., Ammar, M., Rana, M.S.
308	25.	and Ali, Q, Genomic surveillance reveals the detection of SARS-CoV-2 delta, beta, and gamma
310	~ ~	<i>VOCs during the third wave in Pakistan.</i> Journal of Medical Virology, 2022. 94 (3): p. 1115-1129.
311	24.	Challen, R., et al., Risk of mortality in patients infected with SARS-CoV-2 variant of concern
312		202012/1: matched cohort study. BMJ, 2021. 372 : p. n579.
313	25.	Reichert, E., et al., Methods for early characterisation of the severity and dynamics of SARS-CoV-
314		2 variants: a population-based time series analysis in South Africa. The Lancet Microbe, 2022.
315		3 (10): p. e753-e761.
316	26.	Wolter, N., et al., Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in
317		South Africa: a data linkage study. Lancet, 2022. 399 (10323): p. 437-446.
318	27.	Skarzynski, M., et al., SARS-CoV-2 Genome-Based Severity Predictions Correspond to Lower qPCR
319		Values and Higher Viral Load. Glob Health Epidemiol Genom, 2022. 2022: p. 6499217.
320	28.	Hall, V., et al., Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.
321		N Engl J Med, 2022. 386 (13): p. 1207-1220.

- 322 29. Nadeem, I., et al., Safety and efficacy of Sinopharm vaccine (BBIBP-CorV) in elderly population of
 323 Faisalabad district of Pakistan. Postgrad Med J, 2022.
- 32430.Nisar, M.I., et al., Assessing the effectiveness of COVID-19 vaccines in Pakistan: a test-negative325case-control study. J Infect, 2023.

328 Table 1. Clinical characteristics associated with non-severe as compared with

329 severe/critical COVID-19

Variables	Non-severe (n=95)	Severe/critical (n=102)	Unadjusted OR (95% CI)	p-value	
Age Range (years)					
<50	60 (63.2)	22 (21.6)	(Ref)	< 0.001	
>=50	35 (36.8)	80 (78.4)	6.23 (3.32-		
			11.7)		
Median (IQR)	(n=95) (n=102) OR $60 (63.2)$ $22 (21.6)$ (Ref. $35 (36.8)$ $80 (78.4)$ 6.23 $37 (28-60)$ $65 (50-74)$ 1.05 $37 (28-60)$ $65 (50-74)$ 1.05 11.77 $37 (28-60)$ $65 (50-74)$ 1.05 11.77 $37 (28-60)$ $61 (59.8)$ $(Ref.)$ $41 (43.2)$ $61 (59.8)$ $(Ref.)$ $54 (56.8)$ $41 (40.2)$ 0.51 0.90 0.90 0.90 $20 (37.0)$ $3 (7.3)$ 0.13 0.49 0.40 0.49 $21 (22.1)$ $60 (58.8)$ 5.03 $30 (31.6)$ $64 (62.8)$ 3.65 $10 (10.5)$ $29 (28.4)$ 3.38 7.39 $2 (2.1)$ $18 (17.7)$ 9.96 44.2 44.2 44.2 $11 (1-2)$ $3 (2-8)$ 7.52 $11 (1-2)$ $3 (2-8)$ 7.52 $1 (1-3)$ $7 (3-15)$ 1.18 <	1.05 (1.03-	< 0.001		
			1.07)		
Gender					
Male			· · ·	0.019	
Female	54 (56.8)	41 (40.2)	0.51 (0.30-		
			/		
Pregnant	20 (37.0)	3 (7.3)	0.13 (0.37-	0.001	
			0.49)		
Co-morbid					
conditions					
DM	21 (22.1)	60 (58.8)	5.03 (2.69 -	< 0.001	
			9.40)		
HTN	30 (31.6)	64 (62.8)	3.65 (2.02-	< 0.001	
			6.58)		
IHD	10 (10.5)	29 (28.4)	3.38 (1.54-	0.002	
			7.39)		
CKD	2 (2.1)	18 (17.7)	9.96 (2.24-	< 0.001	
			44.2)		
WHO Ordinal		Median (IQR)			
score			0.00 (1.00	0.001	
At admission	3 (1-4)	5 (5-6)	8.02 (4.38-	< 0.001	
			14.69)		
At discharge	1 (1-2)	3 (2-8)	7.52 (3.42-	< 0.001	
			16.54)		
LOS	1 (1-3)	7 (3-15)	1.18 (1.10-	< 0.001	
			1.27)		
Outcome at	n (%)	n (%)		<0.001	
discharge		П (70)		<0.001	
U	1 (1.05)	27 (26 2)	70.1 (9.3 -		
Dead	1 (1.03)	37 (30.3)	70.1 (9.3 - 527.09)		
Alive	91 (95.8)	48 (47.0)	· · · · · · · · · · · · · · · · · · ·		
LAMA	3 (3.2)	17 (16.7)			

Vaccination	n (%)	n (%)		
status				
Unvaccinated	38 (40.0)	54(52.9)	Ref	
Fully vaccinated	36 (37.9)	23 (22.5)	0.45 (0.23 –	0.019
			0.88)	
VoC	n (%)	n (%)		
Non-Omicron	32 (33.7)	56 (54.9)	Ref	
Omicron			0.42 (0.23 –	0.003
	63 (66.3)	46 (45.1)	0.74)	

331 DM: Diabetes Mellitus, HTN: Hypertension, IHD: ischemic heart disease, CKD: chronic kidney

disease, LOS: length of stay, IQR: interquartile range, LAMA: left against medical advice, MI:

333 myocardial infarction, AKI: acute kidney injury, VoC: variant of concern, Non-Omicron include

Alpha, Beta, Delta and Gamma variants.

343 Table 2. Factors associated with COVID-19 severity

Severity of illness	Adjusted Odds Ratio	(95% Confidence	p-value
		Interval)	
Age >= 50	5.73	(2.45-13.7)	< 0.001
Presence of Diabetes	4.24	(1.82-9.85)	0.001
Mellitus			
Fully Vaccinated	0.25	(0.11-0.58)	0.001

344

- 345 A multivariable model was run to investigate factors associated with severity of illness using
- 346 STATA software

347

Variables	Died (n=38)	Alive (n=139)	Unadjusted OR (95% CI)	p-value	Multivariate analysis OR (95% CI)	p- value
Age Range n (%)						
18-29	1 (2.6)	32 (23.0)	(Ref)			
30-49	5 (13.2)	40 (28.8)	4.0 (0.4- 35.9)	0.219		
50-69	16 (42.1)	35 (25.2)	14.6 (1.83- 116.6)	0.011		
>=70	16 (42.1)	32 (23.0)	16.0 (2.0- 127.9)	0.009		
Age						
<50	6 (15.8)	72 (51.8)	Ref			
>=50	32 (84.2)	67 (38.2)	5.73 (2.25- 14.6)	< 0.001	5.07(1.92- 13.42)	0.001
Median Age (IQR) years	64 (55-75)	48 (30- 69)	1.04 (1.02- 1.06)	0.001		
Gender n (%)						
Male	22 (57.9)	66 (47.5)	(Ref)			
Female	16 (42.1)	73 (52.5)	0.66 (0.32-1.36)	0.257		
Co-morbids n (%)						
DM	20 (52.6)	49 (35.2)	2.04 (0.99 - 4.22)	0.054		
HTN	22 (57.9)	59 (42.5)	1.86 (0.90- 3.86)	0.093		
IHD	10 (26.3)	22 (15.8)	1.90 (0.80- 4.46)	0.141		
CKD	4 (10.5)	10 (7.2)	1.52 (0.45- 5.14)	0.503		
Co-infection or secondary infections n (%)	12 (31.6)	22 (15.8)	2.45 (1.08- 5.58)	0.032		
Complications n (%)						
MI	8 (21.1)	7 (5.0)	5.03 (1.69- 14.9)	0.004	5.11(1.45- 17.93)	0.001
AKI	10 (26.3)	12 (8.6)	3.78 (1.48- 9.61)	0.005		
Pneumothorax/pneum omed	4 (10.5)	2 (1.2)	8.05 (1.42- 45.8)	0.019		

349Table 3: Clinical characteristics of COVID-19 patients associated with mortality

Laboratory parameters						
At Day 1						
CRP (mg/L)<100	17 (44.7)	59 (42.4)	Ref			
(Ref)	, , , , , , , , , , , , , , , , , , ,	× ,				
CRP >=100	21 (55.3)	80 (57.6)	0.91 (0.44-	0.80		
			1.87)			
	7 (10 4)	40 (20.0)	D.C.			
D-Dimer (mg/L)<1.5 (Ref)	7 (18.4)	40 (28.8)	Ref			
D-Dimer >1.5	31 (81.6)	99 (71.2)	1.78 (0.72-	0.204		
			4.39)			
Vaccination status*						
Fully vaccinated	5 (13.1)	47 (33.8)	Ref			
Unvaccinated	20 (52.6)	64 (46.0)	2.94(1.02-	0.044		
	20 (32.0)	01(10.0)	8.39	0.011		
VoC n (%)						
alpha	7 (18.4)	17 (12.2)	(Ref)			
beta	8 (21.0)	18 (12.9)	1.07 (0.32-	0.902		
ocia	0 (21.0)	10 (12.7)	0.62)	0.902		
gamma	3 (7.8)	3 (2.2)	2.42 (0.39 -	0.641		
		× ,	15.0)			
delta	8 (21.0)	15 (10.8)	1.29 (0.38 -	0.680		
			4.43)			
Omicron	12 (31.6)	86 (61.9)	0.34 (0.12 -	0.047		
			0.98)			
VoCs	n (%)	n (%)				
Non-Omicron	n (%) 26 (68.4)	n (%) 53 (38.1)	Ref			
Omicron	20 (00.4)	33 (30.1)	0.28(0.13-	0.001	0.22(0.10-	0.001
	12 (31.6)	86 (61.9)	0.28(0.13-0.61)	0.001	0.22(0.10-0.53)	0.001
	12 (31.0)	00 (01.9)	0.01)	1	0.55)	

351 DM: Diabetes Mellitus, HTN: Hypertension, IHD: ischemic heart disease, CKD: chronic kidney

disease, LOS: length of stay, IQR: interquartile range, MI: myocardial infarction, AKI: acute

353 kidney injury, CRP: C - reactive protein.

*20 patients who left against medical advice and 3 patients who were partially vaccinated wereexcluded.


356

358 Figure Legends

359

Figure 1. SARS-CoV-2 Omicron variants have lower CT values. The amplification thresholds (CT values) of the infecting VoC in SARS-CoV-2 positive nasal specimens of 197 patients was analysed according to the variant type. The graph depicts data for alpha (n=27), beta (n=29), gamma (n=7), delta (n=25) and omicron (n=109) variants. Data shown is for the Orf1ab gene is depicted as per the SARS-CoV-2 Cobas 6800 Roche assay. The horizontal lines depict the median values for each group. The scatter plots depict interquartile ranges (10-90th percentile) for each group. MWU analysis, with 95% significance p<0.05

p=0.0005



CT values